Amgen — Apr 30, 2026 release
Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000318154-26-000054
Showing in the filing
Non-GAAP tax rate
“15.0 % — 16.5 %”
Period
FY2026
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 7
Total revenues for FY2026
“$37.1 billion to $38.5 billion”
Capital expenditures for FY2026
“approximately $2.6 billion”
Share repurchases for FY2026
“not to exceed $3.0 billion”
GAAP diluted EPS for FY2026
“$ 15.62 — $ 17.10”
Non-GAAP diluted EPS for FY2026
“$ 21.70 — $ 23.10”
GAAP tax rate for FY2026
“14.5 % — 16.0 %”
Non-GAAP tax rate for FY2026
“15.0 % — 16.5 %”
Exhibit 99.1 · the passage around this item
… earlier in the release
Reconciliation of GAAP Tax Rate Guidance to Non-GAAP Tax Rate Guidance for the Year Ending December 31, 2026 (Unaudited) GAAP tax rate guidance 14.5 % — 16.0 % Tax rate of known adjustments discussed above 0.5 % Non-GAAP tax rate guidance 15.0 % — 16.5 %
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.